 <h1>Congratulations! 🎉 </h1>
    <p style="color:#637381;">All done! You’ve completed another milestone.</p>

To continue, enter your details to log in.

We’ve sent a 6‑digit code to #MAIL_ADDRESS#\nPlease check your inbox or spam folder and enter the code below to continue.

Verification code sent

Thank you for the payment. You can now access {collectionName} by simply clicking the button below.

Yes, you’ve successfully ordered! 🎉

Unlock This Exclusive Course

It seems that your email address is not currently on the authorized access list. Please ensure you are using the email address that was invited, or contact the content owner for assistance.

Verification Required for Access

Course Introduction and Overview

What This Course Is About

Who This Mini-Course Is For

Teaching Goals

The Core Concepts of ICH Q3B(R2) Scope

Slide 2 — Concept Simplified (60 sec)

10 Key Concepts

Practical Application and Risk Assessment

Slide 3 — Case Study (90 sec)

Slide 4 — Practical Application (60 sec)

10-Point Key Audit / Inspection Checklist

Quiz

Q1. Which of the following is within the scope of ICH Q3B(R2)?

Q2. A new tablet's API is a primary amine; the filler is a reducing sugar. On accelerated stability a new peak appears and rises. A colleague says, "Sugars always throw impurities, it's the excipient, Q3B doesn't apply." The most accurate response is:

Q3. Which products are excluded from Q3B(R2)?

Q4. Q3B(R2) applies to impurity control at which stage?

Q5. A drug-substance process impurity is listed and controlled on the API specification. Under Q3B, in the drug product you should:

Survey/Feedback

Course Content Feedback Survey

Professional Application and Impact Survey

Welcome to "Understanding the Scope of Degradation Products Under ICH Q3B," a specialized mini-course designed for pharmaceutical professionals navigating the complexities of impurity control. In the highly regulated world of drug development, accurately identifying and controlling degradation products is paramount for ensuring patient safety and product quality.

Welcome to "Understanding the Scope of Degradation Products Under ICH Q3B," a specialized mini-course designed for pharmaceutical professionals navigating the complexities of impurity control. In the highly regulated world of drug development, accurately identifying and controlling degradation products is paramount for ensuring patient safety and product quality. However, misinterpreting the scope of the ICH Q3B(R2) guideline can lead to wasted resources, unnecessary control efforts on out-of-scope impurities, and regulatory delays. This comprehensive course provides a deep dive into the strict definition of degradation products within the context of ICH Q3B(R2), focusing specifically on registration applications for new drug products. You will explore the foundational principles of impurity control, differentiating between true in-scope degradants—such as reaction products of the drug substance with excipients or container closure systems—and out-of-scope impurities like leachables, residual solvents, and elemental impurities. Through real-world case studies, practical applications, and a 10-point key audit checklist, you will learn how to map degradation pathways, investigate ambiguous peaks using a risk-based scientific approach, and build a defensible degradant story for regulatory submissions and successful inspections. Whether you are preparing a dossier or defending CMC decisions during an audit, this course equips you with the critical knowledge to prevent scope errors and ensure compliance with ICH Q3B(R2) thresholds.

113. Understanding the Scope of Degradation Products Under ICH Q3B

<div class="simple-box-wrapper">
    <div class="simple-box">
        <div class="column">
            <p>The control of degradation products is a fundamental pillar of pharmaceutical quality assurance, directly impacting patient safety and product efficacy. For professionals tasked with interpreting stability data, drafting Chemistry, Manufacturing, and Controls (CMC) documentation, or approving analytical results, a precise understanding of regulatory boundaries is essential. This course provides a comprehensive examination of the ICH Q3B(R2) guideline, specifically focusing on its application to registration applications for new drug products. By strictly defining what constitutes a degradation product within this framework, the curriculum establishes the foundational principles necessary to distinguish between in-scope degradants—such as active pharmaceutical ingredient (API) interactions with excipients or container closure systems—and out-of-scope impurities like leachables, residual solvents, and process impurities governed by ICH Q3A.</p>

<p>Navigating the complexities of chemical degradation pathways requires more than theoretical knowledge; it demands rigorous, risk-based scientific application. Designed for quality control (QC) analysts, quality assurance (QA) reviewers, CMC writers, and analytical scientists, this program bridges the gap between regulatory theory and daily operational decision-making. Participants will analyze real-world stability findings, investigate ambiguous chromatographic peaks, and formulate defensible control strategies. Through detailed case studies and a comprehensive 10-point audit checklist, learners will acquire the critical skills needed to prevent wasted analytical efforts on out-of-scope impurities, ensure robust regulatory submissions, and confidently defend impurity scoping decisions during regulatory inspections.</p>
        </div>
    </div>
</div>
